QIAGEN NV (QGEN)

39.50
0.55 1.37
NYSE : Health Technology
Prev Close 40.05
Open 39.62
Day Low/High 39.22 / 39.70
52 Wk Low/High 32.33 / 41.55
Volume 889.75K
Avg Volume 1.12M
Exchange NYSE
Shares Outstanding 226.97M
Market Cap 9.09B
EPS 0.80
P/E Ratio 48.84
Div & Yield N.A. (N.A)
QIAGEN Launches QCI Interpret Bioinformatics Features For Use For Blood Cancers As Well As A Novel Myeloid Gene Panel For GeneReader NGS System

QIAGEN Launches QCI Interpret Bioinformatics Features For Use For Blood Cancers As Well As A Novel Myeloid Gene Panel For GeneReader NGS System

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of two novel products to deliver actionable insights on a wide range of blood cancers: a new workflow for the QIAGEN Clinical Insight (QCI) Interpret bioinformatics solution for...

NeuMoDx 288 (Photo: Business Wire)

NeuMoDx 288 (Photo: Business Wire)

QIAGEN N.V.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMGN, CIG.C, COTV, CTRE, GMS, HPT, IAG, NFEC, QGEN, SCVL, THR, TPHS, USFD, UVV Downgrades: BKE, IGT, TSLX, VRX Initiations: MGEN Read on to get TheStreet Quant Ratings' detailed report:

QIAGEN Welcomes WHO's Essential Diagnostics List Which Includes QuantiFERON-TB Gold

QIAGEN Welcomes WHO's Essential Diagnostics List Which Includes QuantiFERON-TB Gold

QIAGEN today welcomed the First Edition of the World Health Organization's (WHO) Essential Diagnostics List, which endorses the use of interferon gamma release assays (IGRAs) for the diagnosis of latent TB infection.

QIAGEN Reports Results For First Quarter 2018

QIAGEN Reports Results For First Quarter 2018

QIAGEN N.V.

TheStreet Quant Rating: B (Buy)